Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
Mediterr J Hematol Infect Dis ; 3(1): e2011053, 2011.
Article in English | MEDLINE | ID: mdl-22220250

ABSTRACT

Acute promyelocytic leukemia (APL) is highly curable with the combination of all-transretinoic acid (ATRA) and anthracycline based chemotherapy, but the percentage of early deaths remains high. In the present study, we report the clinical, immunophenotypic, cytogenetic and molecular characteristics and outcome of APL patients diagnosed and treated in various Hospitals of Greece and Cyprus.We describe the data of ninety-five APL patients who were diagnosed during the last 15 years. Seven (7.4%) newly diagnosed APL patients died due to intracranial hemorrhage within 72 hours of presentation. All but two patients were induced with ATRA alone or ATRA plus chemotherapy. The early death rate was 14.9%. After induction all 80 evaluable patients achieved complete hematologic remission. The cumulative incidence of relapse was 18.3%. Eight of the ten relapsed patients were successfully salvaged, while both patients with molecularly resistant disease died during salvage treatment. Overall survival (OS) at 5 years was 78.4% and disease free survival (DFS) 73.6%. In multivariate analysis of OS age over 60 years, DIC at diagnosis and marginally major hemorrhage at presentation were identified as adverse prognostic factors. In the subgroup of patients with available data on FLT3 mutation status (49 out of 94), ITD positivity also remained as an independent prognostic factor in the final model of OS, together with major hemorrhage and marginally high Sanz score. We found a close correlation between the CD2 expression and the development of the differentiation syndrome (DS). In conclusion, the main problem in managing patients with APL is still the high early death rate.

3.
Oncologist ; 14(12): 1198-200, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19955186

ABSTRACT

The simultaneous occurrence of multiple myeloma (MM) and chronic myeloid leukemia (CML) is an extremely rare event that has been reported in only eight cases in the literature. We report here on only the third case of the development of MM in a patient with CML on treatment with imatinib mesylate, and to our knowledge, this is the first case in a patient who received imatinib as first-line treatment.


Subject(s)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications , Multiple Myeloma/complications , Piperazines/adverse effects , Pyrimidines/adverse effects , Benzamides , Female , Humans , Imatinib Mesylate , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Middle Aged , Multiple Myeloma/chemically induced , Multiple Myeloma/drug therapy , Piperazines/therapeutic use , Protein Kinase Inhibitors/adverse effects , Protein Kinase Inhibitors/therapeutic use , Pyrimidines/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...